Carsten Linnemann, Ph.D., is the President, Chief Executive Officer, and a Co-Founder of Neogene Therapeutics. Before Neogene, Dr. Linnemann served as Associate Director, Next Generation T Cell Therapies and Managing Director of Kite Pharma EU B.V. He has co-founded several biotech companies, including T-Cell Factory B.V. (acquired by Kite Pharma, Inc. in 2015). He has co-authored several publications in the field of genetic engineering of T cells and done seminal work on human neoantigen biology. Dr. Linnemann has been awarded numerous professional honors including the Thesis Prize from the Netherlands Society of Gene and Cell Therapy and the Antoni van Leeuwenhoek Career Achievement Award from The Netherlands Cancer Institute. Dr. Linnemann is an alumnus of the German Academic Foundation and the Boehringer Ingelheim Fonds – Foundation for Biomedical Research. He received a Ph.D. with honors for his work on engineering T cell immunity by TCR gene transfer in the laboratory of Dr. Ton Schumacher at The Netherlands Cancer Institute.
Menu
